MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.15
+0.64
+8.52%
Opening 11:07 04/06 EDT
OPEN
8.06
PREV CLOSE
7.51
HIGH
8.16
LOW
7.89
VOLUME
145.14K
TURNOVER
--
52 WEEK HIGH
12.63
52 WEEK LOW
3.595
MARKET CAP
371.34M
P/E (TTM)
-3.6164
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CTMX stock price target is 13.82 with a high estimate of 19.00 and a low estimate of 7.00.

EPS

CTMX News

More
  • CytomX Therapeutics (CTMX) Upgraded to Buy: Here's What You Should Know
  • Zacks · 2d ago
  • Will CytomX Therapeutics Continue to Surge Higher?
  • Zacks · 2d ago
  • Top Ranked Momentum Stocks to Buy for April 3rd
  • Zacks · 3d ago
  • The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
  • Benzinga · 6d ago

Industry

Biotechnology & Medical Research
+4.07%
Pharmaceuticals & Medical Research
+3.20%

Hot Stocks

Symbol
Price
%Change

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
More

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.